US FDA-approved monoclonal antibody boosts cancer vaccine's efficacy

摘要

While cancer vaccines can be successful over a short period, eventually the immune system stops responding and the tumor begins to grow again. Tregs are integral to this reduced response, as they regulate the immune system to reduce its response once an infection has been cleared. Tumors exploit Tregs, which even surround the tumor and prevent tumor-fighting cells from reaching the cancerous cells within.